The Small Animal Imaging Shared Resource provides state-of-the-art in vivo molecular imaging capabilities to the investigators of the Kimmel Cancer Center. It was established under the direction of Dr. Mathew Thakur in April 2004 supported, to date, by the Thomas Jefferson University and the Department of Radiology. This resource provides non-invasive small animal imaging, with PET, SPECT, CT and optical imaging. These modalities offer innovative basic, as well as pre-clinical translational, research capabilities for studying patho-physiology and genesis of cancer. In addition to providing comprehensive imaging services the expertise exists to a) custom synthesize probes specific for targeted bio-markers;b) develop new image generation and analysis techniques;and c) train cancer investigators to harness the strengths of molecular imaging. The facility is supported by three AALAC accredited animal houses and two veterinarian staff members. Thus far this shared resource has supported fifteen federally funded investigations related to oncology and enhanced productivity as depicted by several publications in peer-reviewed journals. The facility was used by seven cancer center members.

Public Health Relevance

In recent years, new approaches to drug discovery have been focused upon better understanding of the biochemical pathways that control the genesis of diseases at a molecular level. Once understood. Molecular Imaging (Ml) can extend that knowledge to a new meaningful dimension and contribute extensively to the management of patients suffering from cancer, cardiovascular diseases, neurological disorders and more.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-14
Application #
8517967
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-15
Project End
2018-05-31
Budget Start
2013-06-18
Budget End
2014-05-31
Support Year
14
Fiscal Year
2013
Total Cost
$75,327
Indirect Cost
$26,688
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552
Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35

Showing the most recent 10 out of 807 publications